ENPICOMDiscovery, characterization, and generative deep learning-based humanization of therapeutic antibody candidates
In this on-demand webinar, presented in collaboration with Genovac and Carterra, we explore how HT-SPR platforms like Carterra's LSA® help discover and characterize therapeutic antibodies across multiple species. Learn how to measure binding kinetics and perform epitope binning in a single experiment, and discover how ENPICOM’s software combines sequence diversity, lab data, and in-silico profiles to select lead candidates.
We discuss a robust discovery workflow that combines:
- Beacon® Optofluidic instrument for high-throughput single B cell screening
- Carterra LSA with HT-SPR technology for binding kinetics and epitope binning
- ENPICOM generative deep learning model for AI-based antibody humanization
- GenovacAI humanization service powered by ENPICOM
We illustrate, using an anti-RAGE case study, how these tools can accelerate the discovery process, improve the quality of antibody candidates, and shorten engineering timelines.
Meet the speakers
Andreas Weise is the primary contact for Genovac key accounts throughout the course of antibody discovery, production, and characterization projects. Prior to his employment at Genovac GmbH, Andreas Weise held a deputy professorship in the cell biology department at the University of Albert-Ludwigs-University Freiburg, Germany.
Andreas Weise, PhD
Senior Account Manager
Piotr van Rijssel works closely with pharmaceutical partners, organizing and managing efforts to integrate their research with advanced analytical solutions. By streamlining discovery and development workflows, he supports the efficient development of antibody-based therapies.
Piotr van Rijssel
Senior Application Scientist
Trusted by industry leaders
